Histone deacetylases and cancer: causes and therapies (original) (raw)

• Marks, P. A. & Rifkind, R. A. Erythroleukemic differentiation. Annu. Rev. Biochem. 47, 419–478 (1978).
  CAS PubMed Google Scholar
• Friend, C. et al. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethylsulfoxide. Proc. Natl Acad. Sci. USA 68, 378–382 (1971).Original observation that a chemical — dimethylsulphoxide — can induce terminal differentiation of transformed cells.
  CAS PubMed PubMed Central Google Scholar
• Reuben, R. C. et al. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc. Natl Acad. Sci. USA 73, 862–866 (1976).First report that a group of hybrid polar compounds are potent inducers of transformed cell differentiation.
  CAS PubMed PubMed Central Google Scholar
• Marks, P. A. et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
  CAS PubMed Google Scholar
• Marks, P. A. et al. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. (in the press).
• Gregory, P. D. et al. Histone acetylation and chromatin remodeling. Exp. Cell Res. 265, 195–202 (2001).Shows the role of histone acetylation in chromatin remodelling and regulation of gene expression.
  CAS PubMed Google Scholar
• Deckert, J. & Struhl, K. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol. Cell Biol. 21, 2726–2735 (2001).
  CAS PubMed PubMed Central Google Scholar
• Kochbin, S. et al. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11, 162–166 (2001).
  Google Scholar
• Gray, G. G. & Ekstrom, T. J. The human histone deacetylase family. Exp. Cell Res. 262, 75–83 (2001).
  CAS PubMed Google Scholar
• Urnov, F. D. & Wolffe, A. Chromatin organization and human disease. Emerging Ther. Targets 4, 665–685 (2000).
  CAS Google Scholar
• Mahlknecht, U. & Hoelzer, D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6, 623–644 (2000).
  CAS PubMed PubMed Central Google Scholar
• Timmerman, S. et al. Histone acetylation and disease. Cell. Mol. Life Sci. 58, 728–736 (2001).
  Google Scholar
• Cress, W. D. & Seto, E. Histone deacetylases, transcriptional control and cancer. J. Cell. Physiol. 184, 1–16 (2000).
  CAS PubMed Google Scholar
• Yoshida, M. et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174–17179 (1990).Trichostatin A was one of the first hydroxamic-acid-based inhibitors of histone deacetylases to be identified.
  CAS PubMed Google Scholar
• Kijima, M. et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268, 22429–22435 (1993).
  CAS PubMed Google Scholar
• Newmark, H. L. et al. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 78, 1–5 (1994).
  CAS PubMed Google Scholar
• Kwon, H. J. et al. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95, 3356–3361 (1998).
  CAS PubMed PubMed Central Google Scholar
• Carducci, M. et al. Phenylbutyrate (PB) for refractory solid tumors: phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res. 17, 3972–3973 (1997).
  Google Scholar
• Phiel, C. J. et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734–36741 (2001).
  CAS PubMed Google Scholar
• Saito, A. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 96, 4592–4597 (1999).
  CAS PubMed PubMed Central Google Scholar
• Nakajima, H. et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241, 126–133 (1998).
  CAS PubMed Google Scholar
• Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003–3007 (1998).Shows that a class of hydroxamic-acid-based hybrid compounds that inhibit histone deacetylases are inducers of transformed cell-growth arrest, differentiation and/or apoptosis.
  CAS PubMed PubMed Central Google Scholar
• Kim, Y. B. et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461–2470 (1999).
  CAS PubMed Google Scholar
• Butler, L. M. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165–5170 (2000).Reports that the histone deacetylase inhibitor SAHA, inhibits prostate cancer growth in tumour-bearing animals without toxicity.
  CAS PubMed Google Scholar
• Butler, L. M. et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962–970 (2001).
  CAS PubMed Google Scholar
• Meinke, P. T. & Liberator, P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 8, 211–235 (2001).
  CAS PubMed Google Scholar
• Van Lint, C., Emiliani, S., & Verdin, E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr. 5, 245–254 (1996).Inhibition of histone deacetylases caused a very selective alteration in transcription of expressed genes in transformed cells.
  CAS PubMed Google Scholar
• Huang, L. & Pardee, A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6, 849–866 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kornberg, R. D. & Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98, 285–294 (1999).
  CAS PubMed Google Scholar
• Gregory, P. D., Wagner, K. & Horz, W. Histone acetylation and chromatin remodelling. Exp. Cell Res. 265, 195–202 (2001).
  CAS PubMed Google Scholar
• Davie, J. R. Covalent modifications of histones: expression from chromatin templates. Curr. Opin. Genet. Dev. 8, 173–178 (1998).
  CAS PubMed Google Scholar
• Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).A beginning in identifying the post-translational modifications of histones that alter gene transcription.
  Article CAS PubMed Google Scholar
• Roth, S. Y., Denu, J. M. & Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81–120 (2001).
  CAS PubMed Google Scholar
• Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176–1179 (2000).
  CAS PubMed PubMed Central Google Scholar
• Allfrey, V. G. Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc. Can. Cancer Conf. 6, 313–335 (1966). | PubMed |
  CAS PubMed Google Scholar
• Landry, J. et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl Acad. Sci. USA 97, 5807–5811 (2000).
  CAS PubMed PubMed Central Google Scholar
• Frye, R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793–798 (2000).
  CAS PubMed Google Scholar
• Zhou, X., Marks, P. A., Rifkind, R. A. & Richon, V. M. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl Acad. Sci. USA 98, 10572–10577 (2001).
  CAS PubMed PubMed Central Google Scholar
• Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA 98, 87–92 (2001).
  CAS PubMed Google Scholar
• Zhou, X. et al. Histone deacetylase 4 associates with extracellular signal-regulated kinase 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc. Natl Acad. Sci. USA 97, 14329–14333 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lu, J., McKinsey, T. A., Zhang, C.-L. & Olson, E. N. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 6, 233–244 (2000).
  CAS PubMed Google Scholar
• Bernstein, B. E., Tong, J. K. & Schreiber, S. L. Genome-wide studies of histone deacetylase ion in yeast. Proc. Natl Acad. Sci. USA 97, 13708–13713 (2000).
  CAS PubMed PubMed Central Google Scholar
• Carmen, A. A. et al. Yeast HOS3 forms a novel trichostatinA-insensitive homodimer with intrinsic histone deacetylase activity. Proc. Natl Acad. Sci. USA 96, 12356–12361 (1999).
  CAS PubMed PubMed Central Google Scholar
• Ito, K., Barnes, P. J. & Adcock, I. M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β induced histone H4 acetylation on lysines 8 and 12. Mol. Cell Biol. 20, 6891–6903 (2000).
  CAS PubMed PubMed Central Google Scholar
• Cai, R. L. et al. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J. Biol. Chem. 275, 27909–27916 (2000).
  CAS PubMed Google Scholar
• Robertson, K. D. et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genet. 25, 338–342 (2000).
  CAS PubMed Google Scholar
• Smirnov, D. A., Hou, S. & Ricciardi, R. P. Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class I transcription. Virology 268, 319–328 (2000).
  CAS PubMed Google Scholar
• Giles, R. H., Peters, D. J. & Breuning, M. H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14, 178–183 (1998).
  CAS PubMed Google Scholar
• Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genet. 24, 300–303 (2000).
  CAS PubMed Google Scholar
• Murata, T. et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein–Taybi syndrome. Hum. Mol. Genet. 10, 1071–1076 (2001).Identifies the cause of Rubinstein–Taybi syndrome as a defect in HAT activity as a result of a mutation in the CBP gene.
  CAS PubMed Google Scholar
• Sakai, K., Nagahara, H., Abe, K. & Obata, H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 7, 288–292 (1992).
  CAS PubMed Google Scholar
• Borrow, J. et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nature Genet. 14, 33–41 (1996).
  CAS PubMed Google Scholar
• Liang, J. et al. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92, 2118–2122 (1998).
  CAS PubMed Google Scholar
• Rowley, J. D. et al. All patients with the t(11;16)(q23;p13. 3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90, 535–541 (1997).
  CAS PubMed Google Scholar
• Fenrick, R. & Hiebert, S. W. Role of histone deacetylases in acute leukemia. J. Cell. Biochem. 31 (Suppl.), 194–202 (1998).
  Google Scholar
• Pandolfi, P. P. Transcription therapy for cancer. Oncogene 20, 3116–3127 (2001).
  CAS PubMed Google Scholar
• Dhordain, P. et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 26, 4645–4651 (1998).
  CAS PubMed PubMed Central Google Scholar
• Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S. & Liu, J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA 95, 10860–10865 (1998).
  CAS PubMed PubMed Central Google Scholar
• Wang, J., Saunthararajah, Y., Redner, R. L. & Liu, J. M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 59, 2766–2769 (1999).
  CAS PubMed Google Scholar
• Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to TSA and SAHA. Nature 401, 188–193 (1999).Solved the structure of the catalytic site of an HDAC homologue.
  CAS PubMed Google Scholar
• Jung, M. et al. Analogues of trichostatin and trapoxin B as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 7, 1655–1658 (1997).
  CAS Google Scholar
• Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705–5708 (1996).
  CAS PubMed PubMed Central Google Scholar
• Komatsu, Y. et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with anti-tumor activity. Cancer Res. 61, 4459–4466 (2001).
  CAS PubMed Google Scholar
• Su, G. H., Sohn, T. A. & Ryu, B. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60, 3137–3142 (2000).
  CAS PubMed Google Scholar
• Lavoie, R. et al. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 11, 2847–2850 (2001).
  CAS PubMed Google Scholar
• Murray, P. J. et al. The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg. Med. Chem. Lett. 11, 773–776 (2001).
  CAS PubMed Google Scholar
• Meinke, P. T. et al. Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem. 43, 4919–4922 (2000).
  CAS PubMed Google Scholar
• Kosugi, H. et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn. J. Cancer Res. 92, 529–536 (2001).
  CAS PubMed PubMed Central Google Scholar
• Suzuki, T. et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42, 3001–3003 (1999).
  CAS PubMed Google Scholar
• Prakash, S. et al. Chronic oral administration of CI-994: a phase I study. Invest. New Drugs 19, 1–11 (2001).
  CAS PubMed Google Scholar
• Qui, L. et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80, 1252–1258 (1999).
  Google Scholar
• Parsons, P. G. et al. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. 53, 1719–1724 (1997).
  CAS PubMed Google Scholar
• Richon, V. M. et al. Histone deacetylase inhibitors selectively induce p21 WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014–10019 (2000).
  CAS PubMed PubMed Central Google Scholar
• Sambucetti, L. C. et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274, 34940–34947 (1999).
  CAS PubMed Google Scholar
• Yoshida, M., Horinouchi, S. & Beppu, T. Trichostatin A and novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17, 423–430 (1995).
  CAS PubMed Google Scholar
• Saito, A. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 96, 4592–4597 (1999).
  CAS PubMed PubMed Central Google Scholar
• Xiao, H., Hasegawa, T. & Isobe, K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73, 291–302 (1999).
  CAS PubMed Google Scholar
• Vrana, J. A. et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/ Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18, 7016–7025 (1999).
  CAS PubMed Google Scholar
• MacLeod, K. F. et al. p53-dependentyy and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9, 935–944 (1995).
  CAS PubMed Google Scholar
• Mielnicki, L. M., Ying, A. M., Head, K. L., Asch, H. L. & Asch, B. B. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp. Cell Res. 249, 161–176 (1999).
  CAS PubMed Google Scholar
• Takakura, M. et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 29, 3006–3011 (2001).
  CAS PubMed PubMed Central Google Scholar
• Coffey, D. C. et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61, 3591–3594 (2001).
  CAS PubMed Google Scholar
• Cohen, L. A. et al. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 19, 4999–5005 (1999).
  CAS PubMed Google Scholar
• Brinkmann, H. et al. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J. Biol. Chem. 276, 22491–22499 (2001).
  CAS PubMed Google Scholar
• Kim, M. S. et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med. 7, 437–443 (2001).
  PubMed Google Scholar
• Kwan, H. J. et al. Histone deacetylase inhibitor FK228 inhibits hypoxia-induced tumor angiogenesis. Nature Med. (in the press).
• Gore, S. D. & Carducci, M. A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp. Opin. Invest. Drugs 9, 2923–2934 (2000).
  CAS Google Scholar
• Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid malignancies. Clin. Cancer Res. 7, 2292–2300 (2001).
  CAS PubMed Google Scholar
• Warrell, R. P., He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90, 1621–1625 (1998).
  CAS PubMed Google Scholar
• Novich, S. et al. Initial clinical evaluation of 'transcription therapy' for cancer: all-trans retinoic acid plus phenylbutyrate. Blood 94, 61A (1999).
  Google Scholar
• Kelly, W. K. et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity. ASCO 20, 87A (2001).
  Google Scholar
• Piekarz, R. et al. Histone deacetylase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma. ASCO 20, 232B (2001).
  Google Scholar
• Wozniak, A., O'Shaughnessy, J., Fiorica, J. & Grove, W. Phase II trial of CI-994 in patients with advanced non-small cell lung cancer. ASCO 18, 487A (1999).
  Google Scholar
• Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C. & Evans, R. M. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 2001 Oct 24; [epub ahead of print]. | PubMed |